

FDA Bans Unapproved Oral Colchicine

The FDA has ordered companies to stop manufacturing of unapproved single-ingredient oral colchicine, indicated for daily prevention of gout, to treat acute gout flare-ups, and for the treatment of familial Mediterranean fever. Companies are expected to end manufacturing within 45 days and must stop shipping in interstate commerce within 90 days. *Colcrys* is the only FDA-approved, single-ingredient oral colchicine product available in the US.